Chiome Bioscience Inc. ("Chiome") announced that Chiome and Mologic Ltd. ("Mologic", headquartered in Bedfordshire, United Kingdom) have entered into a Collaborative Research Agreement for antibody discovery and development for use in advanced diagnostic tests. Under this Collaborative Research Agreement for up to 1 year, Chiome will generate specialised antibodies against several novel diagnostic biomarker targets by means of the ADLib® system, Chiome's proprietary antibody generation technology. Mologic will characterize and evaluate the antibodies for application in its advanced diagnostic test platforms. Based on this comprehensive collaboration agreement, Chiome expects to directly contribute to Mologic's leading edge diagnostic work for maximum positive impact on global public health. There is a strong and growing demand for accurate and rapid diagnostic products throughout the world, especially in low to middle income countries (LMICs) suffering from a burden of debilitating infectious diseases, such as tuberculosis and malaria. Chiome will receive research fees from Mologic, and royalties from the profit-making diagnostic products, based on the specialized properties of Chiome antibodies sold in the developed world. Full financial details are not being disclosed.